Oral Telotristat Etiprate Meets Primary Endpoint in Phase III Carcinoid Syndrome Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The TELESTAR trial demonstrated significant benefits in evaluating oral telotristat etiprate in the treatment of cancer patients with carcinoid syndrome, and met its primary endpoint.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login